Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprintingResearch in context

Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprintingResearch in context

Summary: Background: The impact of previous vaccination on protective immunity, duration, and immune imprinting in the context of BA.5-XBB.1.9.1 reinfection remains unknown. Methods: Based on a 2-year longitudinal cohort from vaccination, BA.5 infection and XBB reinfection, several immune effectors...

Full description

Bibliographic Details
Main Authors:	Tingting Cui, Xiaoling Su, Jing Sun, Siyi Liu, Mingzhu Huang, Weidong Li, Chengna Luo, Li Cheng, Rui Wei, Tao Song, Xi Sun, Qi Luo, Juan Li, Jie Su, Shidong Deng, Jincun Zhao, Zhuxiang Zhao, Nanshan Zhong, Zhongfang Wang
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EBioMedicine
Subjects:	SARS-CoV-2 Vaccinated-BA.5-XBB.1.9.1 reinfections Immune imprinting Protection-duration
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396423004693

Similar Items

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
by: Thirumalaisamy P. Velavan, et al.
Published: (2023-03-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
by: Danyi Ao, et al.
Published: (2023-04-01)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
by: Julia N. Faraone, et al.
Published: (2023-12-01)

Distinctive Features of the XBB.1.5 and XBB.1.16 Spike Protein Receptor-Binding Domains and Their Roles in Conformational Changes and Angiotensin-Converting Enzyme 2 Binding
by: Tej Sharma, et al.
Published: (2023-08-01)

Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster
by: Rafael Rahal Guaragna Machado, et al.
Published: (2024-01-01)

The emergence of the Omicron XBB.1.5 variant in India: a brief report on clinical presentation of a few cases
by: Jasmine Samal, et al.
Published: (2023-06-01)

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
by: Cai He, et al.
Published: (2023-06-01)

Transmission and re-infection of Omicron variant XBB.1.5 in hamstersResearch in context
by: Peter J. Halfmann, et al.
Published: (2023-07-01)

The Omicron XBB.1 Variant and Its Descendants: Genomic Mutations, Rapid Dissemination and Notable Characteristics
by: Raffaele Giancotti, et al.
Published: (2024-02-01)

An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants
by: Zongming Liu, et al.
Published: (2023-12-01)

Molecular In-Depth on the Epidemiological Expansion of SARS-CoV-2 XBB.1.5
by: Fabio Scarpa, et al.
Published: (2023-03-01)

An omicron-specific neutralizing antibody test predicts neutralizing activity against XBB 1.5
by: Stephen Varvel, et al.
Published: (2024-01-01)

The assessment of Twitter discourse on the new COVID-19 variant, XBB.1.5, through social network analysis
by: Ikhwan Yuda Kusuma, et al.
Published: (2023-08-01)

Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters
by: Sreelekshmy Mohandas, et al.
Published: (2023-06-01)

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
by: Jin-Jin Chen, et al.
Published: (2023-04-01)

Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023
by: Ighor Arantes, et al.
Published: (2024-03-01)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
by: Md. Aminul Islam, et al.
Published: (2023-04-01)

Monovalent XBB.1.5 booster vaccination induces a broad spectrum of SARS-CoV-2 neutralizing antibodies
by: Nan Huo, et al.
Published: (2024-12-01)

Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant
by: Fabio Scarpa, et al.
Published: (2023-09-01)

The XBB.1.5 slightly increase the binding affinity for host receptor ACE2 and exhibit strongest immune escaping features: molecular modeling and free energy calculation
by: Muhammad Suleman, et al.
Published: (2023-05-01)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024-12-01)

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients
by: Martina Brandolini, et al.
Published: (2023-01-01)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
by: Okesanya Olalekan John, B'MLS, et al.
Published: (2023-12-01)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
by: Masaud Shah, et al.
Published: (2023-09-01)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
by: Andrei A. Pochtovyi, et al.
Published: (2023-09-01)

First identification of the SARS-COV-2/XBB.1.5 sublineage among indigenous COVID-19 cases through the influenza sentinel surveillance system in Niger
by: Adamou Lagare, et al.
Published: (2023-11-01)

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster
by: Julien Favresse, et al.
Published: (2024-06-01)

Retrospective systematic analysis of incidence and severity of COVID-19 reinfection
by: SHI Lei, et al.
Published: (2023-11-01)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
by: Rajesh M. Valanparambil, et al.
Published: (2023-11-01)

SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids
by: Romal Stewart, et al.
Published: (2023-11-01)

Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion
by: Ranjan K. Mohapatra, et al.
Published: (2022-12-01)

Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA
by: Arunachalam Ramaiah, et al.
Published: (2023-09-01)

SARS‐CoV‐2 Omicron variants in Bangladesh: Pandemic to endemic
by: Mohammad Jubair, et al.
Published: (2023-03-01)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
by: Nita Patel, et al.
Published: (2023-11-01)

Twitter-Based Sentiment Analysis and Topic Modeling of Social Media Posts using Natural Language Processing, to Understand People’s Perspectives Regarding COVID-19 Omicron Subvariants XBB.1.5 and BF.7
by: S.V. Praveen, et al.
Published: (2023-03-01)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
by: Srijan Chatterjee, et al.
Published: (2023-06-01)

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
by: Ryuta Uraki, et al.
Published: (2023-11-01)

XBB.1.5 emerges in the Americas: what it means to the region
by: Peter Hotez
Published: (2023-02-01)

Long non-coding RNA XIST promotes retinoblastoma cell proliferation, migration, and invasion by modulating microRNA-191-5p/brain derived neurotrophic factor
by: Yifan Xu, et al.
Published: (2021-01-01)

Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants
by: Lu Li, et al.
Published: (2023-12-01)